Surovatamig for relapsed or refractory B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with follicular lymphoma or large B-cell lymphoma that has come back or not responded after at least 2 prior treatments.
- Your cancer cells show a marker called CD19, which this drug targets.
- You have at least one tumor that can be measured on a scan (at least 1.5 cm in a lymph node or 1 cm in another organ).
- Your blood counts, liver function, and kidney function are within certain acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
This trial tests a new drug called surovatamig against standard radiation therapy (with or without rituximab) for adults with limited stage follicular lymphoma that hasn't been treated before. It may help find a better option for people with this type of cancer.
This study tests a new combination of two drugs (surovatamig and rituximab) for people with follicular lymphoma who have not been treated before. The goal is to see if this combination works better than standard treatments.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.